BCR/ABL antisense oligonucleotides

Drug Profile

BCR/ABL antisense oligonucleotides

Latest Information Update: 20 Jan 2017

Price : $50

At a glance

  • Originator Lynx Therapeutics
  • Class Antisense oligonucleotides
  • Mechanism of Action DNA inhibitors; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myeloid leukaemia

Most Recent Events

  • 20 Jan 2017 Discontinued - Preclinical for Myeloid leukaemia in Canada (unspecified route)
  • 25 Sep 1998 Suspended-Preclinical for Myeloid leukaemia in Canada (Unknown route)
  • 10 Mar 1997 An animal study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top